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http://dxObjective: This study was undertaken to determine whether topical vancomycin would further reduce the inci-
dence of sternal infections in the presence of perioperative antibiotics and tight glycemic control.
Methods:A total of 1075 consecutive patients undergoing cardiac surgery fromDecember 2007 to August 2013
receiving topical vancomycin (2.5 g in 2 mL of normal saline) applied as a slurry to the cut edges of the sternum
were compared with 2190 patients from December 2003 to November 2007 who did not receive topical vanco-
mycin. All patients received perioperative antibiotics (cefazolin 2 g intravenously every 8 hours and vancomycin
1 g intravenously every 12 hours) on induction of anesthetic and continuing for 48 hours; and intravenous insulin
infusions to maintain serum blood glucose level between 120 and 180 mg/dL.
Results: Patients receiving topical vancomycin had less superficial sternal infections (0% vs 1.6%; P<.0001),
deep sternal infections (0% vs 0.7%; P ¼ .005), any type of sternal infection (0% vs 2.2%; P<.0001) and
significantly less sternal infections of any type in patients with diabetes mellitus (0% vs 3.3%; P ¼ .0004).
Conclusions: Topical vancomycin applied to the sternal edges, in conjunction with perioperative antibiotics and
tight glycemic control, helps to eliminate wound infections in cardiac surgical patients. (J Thorac Cardiovasc
Surg 2014;148:1035-40)P
MAlthough the incidence of sternal wound infections has
decreased to 1% to 4% of all cardiac surgical patients,
they are associated with increased morbidity and mortality
and decreased long-term life expectancy.1-4 Sternal wound
infections prolong hospital stay and are now publically
reported.5,6 They can raise hospital costs by as much as
US$62,000.7 The US Center for Medicine and Medicaid
services no longer reimburse hospital costs incurred in the
treatment of deep sternal wound infections after coronary
artery bypass graft (CABG) surgery.8
Several methods have been successful in decreasing the
incidence of sternal wound infections. These include the
use of perioperative antibiotics, glycemic control with
intravenous insulin infusions, and the avoidance of bone
wax.9-13 These therapies have decreased, but have not
eliminated sternal wound infections.
Previous studies have shown that topical antibiotics, used
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The Journal of Thoracic and Carwound concentrations than are possible with systemic anti-
biotics and that this high concentration persists for several
hours after the closure of the wound.14 Vander Salm and
colleagues15 found that using topical vancomycin resulted
in a significant decrease in sternal wound infections in pa-
tients undergoing cardiac surgical procedures. This study
was therefore undertaken to determine whether topical van-
comycin would further reduce the incidence of sternal
wound infections in the presence of perioperative antibi-
otics and tight glycemic control.
METHODS
A total of 3265 consecutive patients undergoing cardiac surgical proce-
dures using a full-length median sternotomy incision at the BostonMedical
Center from December 2003 to August 2013 were included in the study.
Institutional Review Board approval was obtained and the need for consent
was waived because the study design was retrospective and relevant iden-
tifiers were stripped from the data.
Study Groups
All patients received perioperative antibiotics, consisting of cefazolin
(2 g intravenously [IV] every 8 hours) and vancomycin (1 g IV every 12
hours) on induction of anesthetic and continuing for 48 hours after sur-
gery. Intravenous insulin infusions were used starting at the time of in-
duction of anesthetic and continuing for 24 hours to maintain serum
glucose values between 120 and 180 mg/dL.10 From December 2007
to August 2013, 1075 consecutive patients received topical vancomycin.
In these patients, after the median sternotomy, a slurry consisting of 2.5 g
of powdered vancomycin (Eli Lilly Inc, Indianapolis, Ind) diluted in 2
mL of normal saline was prepared in the operative field and applied to
both edges of the cut sternum. The same process was performed imme-
diately before rewiring the sternum. This group of patients was
compared with a cohort of 2190 patients from December 2003 to
November 2007 in whom topical vancomycin was not used. These 2diovascular Surgery c Volume 148, Number 3 1035
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Mtime periods were chosen because there were no changes in the preoper-
ative, intraoperative, or postoperative protocols for patients undergoing
cardiac surgery.
Surgical Technique
Surgical techniques were identical for both groups. All procedures were
performed on heparin-bonded cardiopulmonary bypass circuits with a
membrane oxygenator. The left internal thoracic artery (ITA) was har-
vested as a pedicle graft in all patients with a left anterior descending lesion
greater than 50%. Bilateral ITAs were used at the discretion of the individ-
ual surgeon. The sternum was routinely closed with 4 figure-of-eight ster-
nal cable wires. The fascia, subcutaneous layer, and skin layer were closed
with running, monofilament, absorbable sutures. Antibiotic impregnated
sutures were not used in any patient.
Definition of Sternal Infections
The criteria used for the definition and classification of sternal wound
infections were according to the Centers for Disease Control and Preven-
tion.16 Depths 1 and 2 were defined as a superficial infectious process
limited to the subcuticular and subcutaneous layers with no involvement
of the sternal bone. Depths 3 and 4, which involved the sternal bone or
wires and collections beneath the sternum, were considered deep infec-
tions. Awound was considered infected only if a positive culture for an or-
ganism was obtained. Reported infections included all infections that
developed within 1 year of surgery.
Risk Factors
Patient risk factors were defined according to the Society of Thoracic
Surgeons (STS) Adult Cardiac Surgery Database,17 These included those
factors that have been shown to be associated with a high risk for postop-
erative wound infection and included age, weight, diabetes mellitus, renal
failure, congestive heart failure (CHF), peripheral vascular disease (PVD),
female gender, chronic obstructive lung disease, cardiogenic shock,
myocardial infarction (MI), ejection fraction, urgency of surgery, need
for steroids, and smoking.18
Statistical Analysis
Data are presented as absolute values, percentages, and the mean 
standard deviation. The Fisher exact test and c2 test were used to test sta-
tistical significance for the incidence of sternal wound infections between
the groups. The small incidence of wound infections in the total cohort of
patients did not allow for meaningful multivariable analyses using models
for binary outcomes. Therefore, a propensity-matched score using a greedy
matching algorithm was computed to reduce the selection bias due to the
retrospective nature of the study. The variables used for propensity score
matching included ejection fraction, age, CHF, PVD, endocarditis, dia-
betes, type of surgery, urgency of surgery, smoking, previous MI, preoper-
ative steroids, preoperative creatinine, preoperative weight, crossclamp
time, and cardiopulmonary bypass (CPB) time. Analyses were performed
using SAS version 9.2 software (SAS Institute, Inc, Cary, NC).1036 The Journal of Thoracic and Cardiovascular SurRESULTS
The results are summarized in Tables 1 to 3.
Patient profiles are reviewed in Table 1. There was no dif-
ference between the groups in age, gender, the incidence of
an MI, CHF, diabetes mellitus, PVD, chronic obstructive
lung disease, the need for permanent dialysis, weight, serum
creatinine level, or the urgency of surgery. Patients
receiving topical vancomycin were more likely to have
been active smokers (29% vs 19%; P<.0001) and under-
gone surgery for endocarditis (5% vs 3%; P ¼ .002). Ejec-
tion fraction was slightly higher in the topical vancomycin
group (53.1%  12.5% vs 51.5%  13.7%; P ¼ .001).
Most patients underwent isolated CABG surgery (Table
2). There was a lower incidence of isolated CABG surgery
and a higher incidence of isolated valve procedures in the
patients receiving topical vancomycin. There was no differ-
ence in the incidence of the use of a single ITA (61% van-
comycin vs 63% no vancomycin) or a double ITA (3%
vancomycin vs 3% no vancomycin). The crossclamp times
were 72  33 minutes with no vancomycin versus 67  28
minutes with vancomycin (P< .001) and the CPB times
were 113  40 minutes with no vancomycin versus 105 
48 minutes with vancomycin (P<.001).
The incidence of sternal infections is shown in Table 3.
Patients receiving topical vancomycin had no superficial in-
fections (0% vs 1.6%; P<.0001), no deep sternal infection
(0% vs 0.7%; P ¼ .005), or any type of sternal infection
(0% vs 2.3%; P< .0001) compared with the patients in
whom topical vancomycin was not used. This was particu-
larly evident in patients with diabetes mellitus; patients in
this group receiving topical vancomycin had no infections
(0%) compared with an incidence of 3.3% in patients not
receiving topical vancomycin (P ¼ .0004).
For the 444 patients receiving topical vancomycin who
were propensity matched to 444 patients not receiving van-
comycin, the estimated difference of any sternal infection
was 1.1%. This was statistically significant (P ¼ .02) in
those analyses that accounted for the lack of statistical inde-
pendence imposed by the matching.DISCUSSION
Our results have shown that topical vancomycin, in com-
bination with perioperative antibiotics and tight glycemic
control eliminated both superficial and deep sternal wound
infections in patients undergoing a median sternotomy dur-
ing cardiac surgery. Both groups of patients had a similar
incidence of those risk factors that were shown by Fowler
and colleagues to predict the incidence of postoperative
wound infections.18 Our findings are in keeping with other
studies that have shown that topical vancomycin reduces
sternal wound infections. Vander Salm and colleagues15
found that the use of topical vancomycin prepared as a
slurry, similar to our technique, in conjunction withgery c September 2014








Number 1075 2190 —
Age (y) 65.7  11.6 65.9  12.7 .66
Male/female 741/334 1489/701 .59
Current smoker, n (%) 312 (29) 416 (19) <.0001
Previous myocardial
infarction/heart failure, n (%)
365 (34) 700 (32) .25
Preoperative steroids, n (%) 32 (3) 43 (2) .07
Diabetes mellitus, n (%) 365 (34) 722 (33) .57
Insulin diabetes, n (%) 128 (35) 238 (33) .49
Ejection fraction, n (%) 53.1  12.5 51.5  13.7 .001
Permanent dialysis, n (%) 21 (2) 67 (3) .07
Endocarditis, n (%) 55 (5) 65 (3) .002
Preoperative stroke, n (%) 150 (14) 306 (14) .99
Peripheral vascular disease, n (%) 86 (8) 175 (8) .99
Cardiogenic shock, n (%) 7 (0.6) 13 (0.6) .84
Chronic obstructive pulmonary
disease, n (%)
96 (9) 240 (11) .07
Surgery status
Elective, n (%) 451 (42) 941 (43)
Urgent, n (%) 602 (56) 1204 (55) .86
Emergency, n (%) 22 (2) 45 (2)
Emergency salvage, n (%) 0 (0) 0 (0)
Weight (kg) 84.3  19.2 83.4  18.8 .20
Creatinine (mg/dl) 1.10  0.76 1.11  0.97 .77
Data are presented as the absolute values,%, or the mean  standard deviation.
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Superficial sternal infection, n (%) 0 (0) 34 (1.6) <.0001
Deep sternal infection, n (%) 0 (0) 16 (0.7) .005
All sternal infections, n (%) 0 (0) 50 (2.3) <.0001
All sternal infections among
patients with diabetes
mellitus (%)
0 (0) 24 (3.3) .0004
Data are presented as the absolute values and%.
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Mperioperative systemic antibiotics, reduced the incidence of
sternal wound infections from 3.6% to 0.45% (P¼ .02) in a
blinded, prospective, randomized trial involving 416 pa-
tients. Arruda and colleagues,19 in a retrospective study
involving 1020 patients receiving topical vancomycin,
reduced the incidence of sternal wound infections to
0.49%. Ozzan and colleagues20 studied the effects of
topical vancomycin in a rat model in which the sternum
was inoculated with methicillin-resistant Staphylococcus
aureus. After 7 days, the quantity of organisms in the medi-
astinal bone was significantly decreased in those animals
treated with a combination of systemic IV and topical van-
comycin in contrast to those animals that received only sys-
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CABG, n (%) 591 (55) 1270 (58)
CABG þ valve, n (%) 130 (12) 263 (12) .002
Isolated valve, n (%) 322 (30) 547 (25)
Valve þ other, n (%) 32 (3) 110 (5)
Single ITA, n (%) 656 (61) 1400 (63) .23
Bilateral ITA, n (%) 21 (3) 46 (3)
Data are presented as the absolute values and %. CABG, Coronary artery bypass
graft; ITA, internal thoracic artery.
The Journal of Thoracic and CarConcerns have been raised that the use of topical
vancomycin may result in persistently high levels of
this antibiotic, which may lead to the emergence of
vancomycin-resistant organisms.21 In a previous study
involving 36 patients undergoing a median sternotomy dur-
ing cardiac surgery,22 we sought to determine whether the
use of topical vancomycin, applied as a slurry immediately
after sternotomy and before sternal wiring as in this study,
would result in increased serum vancomycin levels 6 days
after surgery. Serum vancomycin levels were measured on
the evening of surgery and on the sixth postoperative day.
There was a significant decrease in serum vancomycin
levels from 11.5  1.9 mg/mL to 2.12  0.19 mg/mL
(P< .0001). No patient developed a sternal wound infec-
tion. Furthermore, at 1-year follow-up, topical vancomycin
did not potentiate the emergence of drug-resistant infec-
tions or contribute to postoperative renal toxicity.
One theory for the beneficial effects of topical vancomy-
cin is that it may promote sternal union and accelerate the
healing process making it less likely for bacteria to colo-
nize. We did not observe any evidence of sternal instability
or nonunion in patients treated with vancomycin, even those
with diabetes mellitus. This potential mechanism may be
similar to that seen with gelatin-thrombin sealant, which
acts as an osteoinductive protein that stimulates fibroblast
growth,23 This provides a matrix for osteoblast transloca-
tion, thus promoting bone formation, thereby reducing the
risk of sternal nonunion and osteomyelitis.24 In addition,
the antimicrobial effect of vancomycin minimizes bacterial
ingrowth and inoculation of bone.
Topical vancomycin has also been shown to decrease
wound infections in other groups of patients undergoing
surgical procedures, including spinal surgery,25 neurosur-
gery involving cranioplasty,26 dental procedures involving
bone implants,27 and to reduce the incidence of preperito-
neal pocket infections in patients undergoing implantation
of a left ventricular assist device.28 There are several advan-
tages to the use of topical vancomycin. It is easy to prepare
and handle, and is relatively inexpensive. It has no systemic
or local adverse effects. It provides effective hemostasis for
bleeding from the sternum because it readily adheres to cut
bone surfaces or open bone fractures. It also providesdiovascular Surgery c Volume 148, Number 3 1037
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Mbacteriostatic and bacteriocidal protection against gram-
positive organisms that normally cause infections such as
Staphylococcus and Streptococcus.
Our study has several limitations. It is retrospective, from
a single center, and involves separate time periods. Howev-
er, the sample size is large and there were no changes in
perioperative protocols involving antibiotics, surgical tech-
niques, or postoperative care during the study period. Pro-
pensity matching was used to ensure that the risk factors
known to cause sternal infections were evenly matched be-
tween the groups. Although the crossclamp and CPB times
were statistically longer in the no vancomycin group, the
differences are small (5 minutes crossclamp time and 8 mi-
nutes CPB time). Furthermore, our propensity-matched
subset analysis, which took into account crossclamp and
CPB times, showed a 1.1% difference in any sternal infec-
tions, which was statistically different (P ¼ .02).
We conclude that topical vancomycin in combination
with perioperative antibiotics and tight glycemic control
eliminates sternal infections in patients undergoing cardiac
surgical procedures. Consideration should be given to using
topical vancomycin in all patients undergoing a median
sternotomy.
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Dr Thomas J. Vander Salm (Salem, Mass). Thank you, Har-
old, and congratulations for a very important paper.
In 1981, we replaced bone wax with a mixture of topical
thrombin, powdered gel foam, and vancomycin applied to the
cut sternal edges. In 1989, we published a study in the Journal
of Thoracic and Cardiovascular Surgery on 416 patients assigned
to with 2 arms, 1 of which contained the vancomycin in the afore-
mentioned mixture, and the other that did not. We had a 7-fold
reduction in infection in the vancomycin arm, and we have used
it ever since. In our last 2000 patients, we had 1 sternal or medias-
tinal infection. I’m delighted to see the results of this much larger
study in which the vancomycin arm had no infection.
I have 3 questions for you. You address the drawbacks in your
manuscript of this being a retrospective study with 2 arms being
consecutive rather than simultaneous. Do you think it ethically
feasible to conduct this as a randomized or a prospective study?
Dr Lazar. Well, first of all, thank you, Dr Vander Salm, for
coming up here and discussing this paper. A lot of this is based
on your initial findings.
I think that the data from this study and from your previous
studies as well as those of others are so convincing that to try togery c September 2014
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Mdo a prospective randomized study would be unethical and would
not give us any more data that we already have.
Dr Vander Salm. I was hoping you would give that answer.
Your dose of vancomycin applied to the sternum was 10 times
what we have used and you use it twice. How did you arrive at that
dose and should we switch?
Dr Lazar. The doses of vancomycin used in all the papers have
varied. In your report, you used 250 mg. Others have used 1 g in 2
mL of normal saline with excellent results. Recently, Filardo from
Baylor reported using 2 g and 2 mL of normal saline.
There is actually a patent on powdered vancomycin in which the
authors have reported 1 to 3 g per 2 mL of normal saline. We
derived our dose from another institution that was using it, and
that’s why we did the subanalysis in a group of 35 to 40 patients,
to show that even at that dose, there was no significant increase in
vancomycin levels.
I can say that the more you use, the more it has a consistency
that allows you to spread it on the sternum. And I noticed that in
your study, you also used a topical thrombin gel, which gives it
more of a consistency.
Dr Vander Salm. And, finally, I note that you close your me-
dian sternotomies with figure-of-eight cables as do we. The ortho-
pedic literature gives very convincing evidence of increased
susceptibility to infection at fracture sites when there is instability.
Do you believe, as we do, that the figure-of-eight cables mark-
edly increase stability of the sternotomy and thereby account for
some of your good results?
Dr Lazar.We also favor the use of the cables, and we’ve been
using them since 1999. In the earlier group, we did have wound in-
fections with the cables. I think the advantage of the cables is that,
in more fragile sternums, it does give you more of a feeling of sta-
bility without overtightening the sternum. The cables don’t cut
through.
But in those patients who had infections earlier that had cables,
we actually had to take the cables out, whereas if it is a superficial
infection with a wire, we can leave the wire in.
But your point is very well taken, and sternal stability is very
important. And in this latter group of patients in whom I used
the vanco paste, as opposed to what we saw before, we did not
see any evidence of any sternal instability. There was no nonunion.
One theory as to why vanco paste works is that it incites an in-
flammatory response that probably increases fibroblast formation.
This has been studied in basic science models. I think this tends to
make the bone stronger and sturdier and decreases the space for
bacteria to grow.
I think it promotes sternal healing, and at the same time acts as a
bactericidal agent.
Dr Irene J. Cybulsky (Hamilton, Ontario, Canada). We
recently reviewed antibiotic use at our center in Hamilton, and
our infection control people are quite concerned about dosing.
Having reviewed the Society of Thoracic Surgeons’ articles
about antibiotic use, I wonder if you could comment on why
you used both vancomycin and Ancef intravenously, whether
you used the current recommendation of 2 g of Ancef and 3 g
for bigger people, and why you feel that you need to monitor
vanco levels for 6 days when most perioperative therapy need
not be more than a maximum of 48 hours.
Dr Lazar. There are a number of parts to your question.The Journal of Thoracic and CarFirst, the title of the slide was eliminates, and I think that if you
really want to eliminate, and I mean zero percent, no infections, I
think you have to go with perioperative antibiotics and tight glyce-
mic control and the use of the vanco paste. I would be a little leery
about trying to cut back on 1 component because I think since 2007
we haven’t seen a single wound infection on the service.
Dr Cybulsky. So just to follow up about your glycemic control,
we recently audited that, and we have good intravenous control
when we use the drip. But then as soon as the patients leave the
intensive care unit and go to the ward, control goes out of control.
So I wonder if you can comment on the duration of your intra-
venous therapy and how long you monitored good glycemic con-
trol. Did you have it ongoing for 6 days?
Dr Lazar. Our protocol is that they all receive intravenous gly-
cemic control starting in the operating room and for the time that
they’re in the intensive care unit.
We actually have a group of endocrinologists, a glycemic con-
trol monitoring group, who then follow them once they’re off the
drip. So when they leave the intensive care unit, they’re off the
drip. They then go with a short-acting insulin agent, and their
glucose levels are monitored until the time they go home.
But the most intensive monitoring occurs in the operating room
in the first 24 hours after surgery and while they’re in the intensive
care unit. We think that that’s probably the most vulnerable time.
Dr John S. Ikonomidis (Charleston, SC). Harold, congratula-
tions on a terrific study with fantastic and really practice-changing
results.
I don’t know if I missed it, but when you showed the slide on the
incidence of infections, did you include superficial wound infec-
tions as well?
Dr Lazar. Yes.
Dr Ikonomidis. So you’re saying since 2007, you haven’t seen
even a single superficial wound infection with this protocol?
Dr Lazar. That’s true. I don’t think it’s becausewe’re better sur-
geons or our techniques are better. I really do think it’s the
vancomycin.
Dr Ikonomidis.And the second question is that considering our
knowledge about the anatomy of the internal thoracic arteries and
what happens to the vascularization of the sternum when they’re
taken down leads me to wonder whether you were able to demon-
strate a difference in vancomycin levels in patients who had single
mammaries, bilateral mammaries, or skeletonized mammaries. I
wonder if you could comment on that.
Dr Lazar.We don’t have a large experiencewith bilateral mam-
maries. But I can tell you that even with bilateral mammaries, at
least in the last 7 years, we haven’t seen any infections.
As far as the diabetics are concerned, in all the patients who had
their levels measured, they all went back down to subtherapeutic
levels.
Dr Ani C. Anyanwu (New York, NY). I have no disclosures.
Given that, I can understand how you can have a lack of gram-pos-
itive infections with vancomycin, but I find it hard to understand
how you don’t see gram-negatives too. And I would argue that
the results you see are not because of vancomycin. There is some-
thing else you are doing.
Andmy question to you is if everyone in this audience and every
surgeon at this meeting started using vancomycin paste, do you
really think we would eliminate sternal wound infections?diovascular Surgery c Volume 148, Number 3 1039
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MDr Lazar. The answer to your question is yes.
And the second part to your question is that we have operated on
a number of patients in this group with endocarditis due to gram-
negative organisms. I have not seen any infections.
Dr Charles M. Geller (New York, NY). My question is actually
very similar to Dr Anyanwu’s. A number of institutions of late
have been reporting an increased incidence of gram-negative as
well as antibiotic-resistant organism sternal wound infections,
especially in diabetic patients.1040 The Journal of Thoracic and Cardiovascular SurDo you feel that the morewidespread use of topical vancomycin
could contribute to this phenomenon as opposed to actually elim-
inating sternal wound infection?
Dr Lazar. No, I disagree. I know a lot of people are using this.
They just haven’t reported their results.
I find that even our trauma service has used it on trauma patients
and open thoracotomies andwound closures, our orthopedic surgeons
are using it for their implants and putting it around bone surfaces.
They haven’t reported their results, but they have seen no infections.gery c September 2014
